Article

Piramal Pharma has committed to reducing absolute Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25% by 2030. Their sustainability journey has evolved from compliance-focused efforts to embedding ESG principles into their core operations.

The company emphasizes collaboration with suppliers and digital transformation initiatives to enhance agility and quality. Achieving zero hazardous waste to landfill and a robust recycling system are key milestones. Looking ahead, they aim to tackle climate resilience and improve supply chain sustainability while fostering a diverse and accountable workplace.